Company intelligence / Profile preview
WBL Biotech
Hangzhou, Zhejiang, Chinawblbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
WBL Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for inflammatory and autoimmune diseases. The company leverages its proprietary drug discovery platform to target key pathways in the immune system, with a particular emphasis on dermatology and respiratory conditions. Its lead programs include small molecule inhibitors and monoclonal antibodies designed to provide superior efficacy and safety profiles compared to existing treatments. WBL Biotech aims to address significant unmet medical needs in chronic inflammatory disorders through precision medicine and advanced molecular engineering.
- Therapeutic areas
- PulmonologyDermatology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on WBL Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WBL Biotech.